

# CANADIAN GUIDELINES ON SEXUALLY TRANSMITTED INFECTIONS (2008 UPDATE)

## V – MANAGEMENT AND TREATMENT OF SPECIFIC INFECTIONS

### HEPATITIS B VIRUS INFECTIONS (Updated January 2010)

#### References

1. Zou S, Zhang J, Tepper M, et al. Enhanced surveillance of acute hepatitis B and acute Hepatitis C in four health regions in Canada 1998–1999. *Can J Infect Dis* 2001;12:345–350.
2. Sherman M. Update 5: June 1996. The epidemiology of hepatitis B in Canada. The Hepatitis Information Network Web site. Available at: [www.hepnet.com/update5.html](http://www.hepnet.com/update5.html). Accessed January 9, 2006.
3. Delage G, Montplaisir S, Remy-Prince S, Pierri E. Prevalence of hepatitis B virus infection in pregnant women in the Montreal area. *CMAJ* 1986;134:897–901.
4. Baikie M, Ratnam S, Bryant DG, et al. Epidemiologic features of hepatitis B virus infection in Northern Labrador. *CMAJ* 1989;141:791–795.
5. Martin JD, Mathias RG. HIV and hepatitis B surveillance in First Nations alcohol and drug treatment centers in British Columbia, Canada. *Int J Circumpolar Health* 1998;57(suppl 1):280–284.
6. Romanowski B, Campbell P. Sero-epidemiologic study to determine the prevalence and risk of hepatitis B in a Canadian heterosexual sexually transmitted disease clinic population. *Can J Public Health* 1994;85:205–207.
7. Zhang J, Zou S, Giulivi A. Viral hepatitis and blood-borne pathogens in Canada. Hepatitis B in Canada. *Canadian Commun Dis Rep* 2001;2753:10–12.
8. *Canadian Immunization Guide*. 7th ed. Ottawa, ON: Public Health Agency of Canada; 2006.
9. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B will respond to alpha interferon therapy? A statistical analysis of predictive factors. *Hepatology* 1989;10:761–763.
10. Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. *Gastroenterology* 1997;113:1258–1263.
11. Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. *MMWR Recomm Rep* 2002;51(RR-6):1–78.
12. *Canadian Consensus Conference on the Management of Viral Hepatitis 2003/2004*. Ottawa, ON: Health Canada and Correctional Service Canada; 2004. Available at: [www.phac-aspc.gc.ca/hepc/hepatitis\\_c/pdf/ccc\\_04/index.html](http://www.phac-aspc.gc.ca/hepc/hepatitis_c/pdf/ccc_04/index.html). Accessed: 10 January 2006.
13. Sherman M, Bain V, Villeneuve J-P, et al. The management of chronic viral hepatitis: a Canadian consensus conference 2004. *Can J Infect Dis Med Microbiol* 2004;15:313–326.
14. Main J, Brown JL, Howells C, et al. A double-blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. *J Vir Hepatitis* 1996;3:211–215.
15. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dopivoxil therapy. *Hepatology* 1999;29:1863–1869.
16. Cotonat T, Quiroga JA, Lopez-Alcorocho JM, et al. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients. *Hepatology* 2000;31:502–506.
17. Rockstroh JK. Management of hepatitis B and C in HIV co-infected patients. *J Acquir Immune Defic Syndr* 2003;34 (suppl 1):S59–S65.